The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Radiomic features predict DFS in neoadjuvant-treated NSCLC
Lukas Delasos, DO, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the association between radiomic features from pre-treatment CT scans and disease-free survival (DFS) in patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy. A radiomic risk score derived via LASSO regression successfully stratified patients into high- and low-risk groups for recurrence. The model outperformed PD-L1 expression in prognostic value, suggesting radiomics may serve as a non-invasive biomarker to guide treatment decisions and surveillance strategies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
